For more than two decades, the chemotherapy drug gemcitabine has been a mainstay treatment for several types of cancer, producing remissions in many patients on its own or conjunction with other drugs. Now, scientists at Dana-Farber Cancer Institute have uncovered, for the first time, genetic evidence of which patients with high-grade serous ovarian cancer (HGSOC) are likely to benefit from the drug.
In a study in the journal Nature Communications, the researchers identified a biomarker – a genetic signature within HGSOC tumor cells – indicating the cells are experiencing “high replication stress,” or RS-high. Cells in this state, struggling to replicate their DNA at high speed, are especially susceptible to gemcitabine, researchers found.
The discovery was followed by another that came as a surprise: In patients whose tumor cells had high replication stress, a combination of gemcitabine and a complementary agent was no more effective than gemcitabine alone in quelling the cancer. Equally surprising was the discovery that tumors with low replication stress responded poorly to gemcitabine itself but succumbed to the two-agent therapy.
The findings offer a way for doctors to identify patients with HGSOC who stand to benefit from the combination therapy and those for whom gemcitabine works well on its own. Investigators are planning a large, phase 3 clinical trial comparing gemcitabine to the tandem therapy in this group of patients, hoping to confirm the findings of the Nature Communications study.
“Patients with HGSOC that has become resistant to platinum-based chemotherapy drugs have a compelling need for better treatments,” says Dana-Farber’s Panagiotis Konstantinopoulos, MD, PhD, the first and corresponding author of the new study. “A new class of compounds called ATR inhibitors, which target the DNA-replication process in rapidly dividing cancer cells, has shown a great deal of promise in laboratory studies.
Panos Konstantinopoulos, MD, PhD
“In a previous clinical trial, our group showed that a combination of gemcitabine and the ATR inhibitor berzosertib enabled many patients with HGSOC to live substantially longer before their disease worsened than patients treated with gemcitabine alone,” he continues. “For the current study, we looked for a biomarker that could predict response to the therapy.”
Replication stress is a byproduct of the amped-up pace of cell growth and division in many tumors. While faster growth confers certain advantages, it also puts enormous strain on the portion of the cell cycle in which cells copy their DNA prior to dividing. Like a factory ordered to operate at double time, a cell racing to duplicate its DNA is apt to make more mistakes than one functioning at normal speed. The accumulation of miscopied strands of DNA represents a direct threat to a tumor’s future: without an intact genetic code, its constituent cells are ill-equipped to survive.
Amid this unbridled haste and error, the ATR protein exerts a steadying, meticulous influence. It halts the cell cycle so DNA can be checked for mistakes and summons other proteins to make the necessary corrections. Its role, in effect, is to save cancer cells from themselves.
ATR’s importance to cancer cells’ survival makes it an appealing target for therapy. If it’s knocked it out of commission by a drug agent, cancer cells may resume the careless ways that ultimately weaken them.
Konstantinopoulos and his colleagues put that strategy to the test in their earlier clinical trial. The hypothesis was that the combination of gemcitabine (which hampers cancer cells from copying their DNA) and berzosertib would undermine DNA replication to a point that would be lethal to cancer cells.
The trial was largely a success, with many patients benefiting from the dual therapy. For the new study, researchers analyzed tumor samples from 57 patients who participated in the trial, looking for mutations or alterations in hundreds of genes. They found that RS-high tumors carried any of eight abnormalities – including the loss of the genes RB1 or CDKN2A or surplus copies of the genes CCNE1, KRAS, or MYC. Tumors without any of these flaws were considered RS-low.
The study’s follow-up finding – that RS-high tumors respond no better to gemcitabine plus berzosertib than they do to gemcitabine alone, whereas RS-low tumors are more susceptible to the combination – at first seems contradictory. Konstantinopoulos explains the results this way: “In cells with high replication stress, gemcitabine creates enough additional stress that the cells die. In cells with low replication stress, gemcitabine increases the stress, but not to the point where they die. The addition of an ATR inhibitor brings the stress up to the necessary lethality level.”
“Our discovery of a novel biomarker for response to gemcitabine in patients with HGSOC is an important step in personalizing treatment for this disease, he remarks. “We’re eager to validate this finding in the new clinical trial currently being planned.”
The senior author of the study is Geoffrey I. Shapiro, MD, PhD, of Dana-Farber. The co-authors are Elizabeth K. Lee, MD, Su-Chun Cheng, ScD, Bose Kochupurakkal, PhD, Joyce F. Liu, MD, Elizabeth H. Stover, MD, PhD, Jennifer Curtis, Nabihah Tayob, PhD, Madeline Polak, Dipanjan Chowdhury, PhD, Ursula A. Matulonis, MD, and Alan D. D’Andrea, MD, of Dana-Farber; Alexandre Andre B.A. da Costa, of AC Camargo Cancer Center, Sao Paulo, Brazil; Doga Gulhan, PhD, of Harvard Medical School; Andrea E. Wahner Hendrickson, MD, of the Mayo Clinic; David L. Kolin, MD, PhD, of Brigham and Women’s Hospital; Elise C. Kohn, MD, of the National Cancer Institute; and Anniina Farkkila, MD, PhD, of the University of Helsinki, Helsinki, Finland.
This study was funded by the National Cancer Institute-Cancer Therapy Evaluation. It was also supported by National Institutes of Health grant UM1 CA186709, by supplements to grant UM1 CA186709, and by the Dana-Farber/Harvard Cancer Center Specialized Program of Research Excellence (P50CA240243) in Ovarian Cancer.
